Pharmaceuticals, 2022 · DOI: https://doi.org/10.3390/ph15040460 · Published: April 11, 2022
Spinal cord injury (SCI) disrupts pathways between the brain and spinal neurons, leading to sensory-motor function loss and respiratory impairments, increasing cardiovascular risk. Current treatments don't restore motor function. Serotonin 1A receptor agonists show promise as neuromodulators, potentially improving function by activating spared motoneurons. Serotoninergic 1A (5-HT1A) agonists can lead to temporary motor function recovery when used alone. Their effectiveness increases when combined with pharmacotherapies, exercise, or spinal stimulation. This review explores the value of 5HT1A receptor agonist therapies for motor and respiratory limitations in SCI. It also discusses mechanistic hypotheses and clinical impact for the potential benefit of 5-HT1A agonist pharmacology in inducing neuroplasticity and improving locomotor and respiratory functions in SCI.
Combining 5-HT1A agonists with exercise, spinal stimulation, or other drugs may lead to greater improvements in motor and respiratory function compared to monotherapy.
5-HT1A agonists can improve respiratory function and reduce sleep-disordered breathing in individuals with SCI, which could lead to better overall health and quality of life.
5-HT1A agonists have the potential to enhance locomotor recovery and muscle coordination in individuals with SCI, especially when combined with rehabilitation strategies.